CCE Techer Talk
The annual CCE Techer Talk, presented by CCE and the Office of Advancement and Alumni Relations, is back!
Join our CCE Chair's Council and alumni as they share their graduate school and postdoc experience, offer guidance to current CCE students and postdocs, give tips for entering today's job market and more.
Date: Friday, September 29th
Time: 3:30–4:30 p.m.
Location: Noyes 147
Light refreshments will be served.
About the Panelists:
Dr. Norbert Bischofberger, CCE Chair's Council member, President and CEO of Kronos Bio
Norbert joined Kronos Bio in 2018 as President and CEO. Prior to joining Kronos Bio, Norbert was the Executive Vice President, Research and Development and Chief Scientific Officer at Gilead Sciences. Norbert joined Gilead in 1990 as Director of Chemistry after having worked as a Senior Scientist in Genentech's DNA Synthesis Group from 1986 until 1990. During his 28-year tenure at Gilead, Norbert presided over the development and approval of more than 25 medicines for a range of serious conditions which led the transformation of the treatment of diseases such as HIV, HCV and lymphoma. Norbert was part of the core management team that grew Gilead from less than 50 employees with no revenues to 10,000 employees with $25B in revenue. In addition to Kronos Bio, Norbert serves on the Supervisory Board of Bayer AG and Board of Directors of Morphic Therapeutic.
Dr. Rui Vogt Alves da Cruz, CCE Chair's Council member, Vice President of Core R&D at Dow
Rui Cruz is currently the Vice President for Dow Core R&D, a global Research and Development organization which drives the long-term R&D vision for Dow. Critical capabilities include High Throughput R&D, Computational Modeling, Artificial Intelligence, Quantum Computing, Formulation &Material Science, Recruiting, Analytical, University and Government Relations and External Funding, Sustainability &Life Cycle Analysis, and Engineering& Process Sciences.
Prior this role, Rui was the Senior Regional R&D Director for the Europe, Middle East, Africa region and Core R&D Director for Europe. He joined Dow in Brazil in 2001, having worked in Human Resources, Customer Services, Technical Services, and Research and Development for several different businesses and technologies. In 2014, he received the prestigious HENAAC Great Minds of STEM Professional Achievement Award and in 2020, received the inaugural AIChE Management Division Young Leader Award.
Dr. JeenJoo "JJ" Kang, PHD '15 CH (Dervan Group), Founder and CEO of Appia Bio
JJ Kang, PhD, is co-founder and CEO. Prior to starting Appia Bio, JJ was a partner on the investment team at The Column Group, a life sciences venture capital firm, and served on the boards of portfolio companies Tenaya Therapeutics, Exonics Therapeutics, and Escient Pharmaceuticals. Prior to that, she worked at FibroGen in project management and corporate strategy. JJ earned a PhD in chemical biology at Caltech and a BA in chemistry from Harvard University.